Cue Health

Cue Health, Inc. is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care. It enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. The firms first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. The company was founded by Ayub Khattak and Clint Sever in 2010 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Nobilis Health Corp. engages in the operation and development of outpatient surgery centers. The firm owns and manages ambulatory and acute care facilities to deliver innovative surgical services. It operates through Medical Services and Marketing Services segment. The Medical Services segment provides the operation of hospitals, outpatient facilities, and other various related health care services. The Marketing Services segment provides marketing services, patient education services, and patient care coordination management services. The company was founded on March 16, 2007 and is headquartered in Houston, TX.

NEW YORK and SAN DIEGO, Nov. 1, 2021 /PRNewswire/ --  Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, and Major League Baseball (MLB) today announced that Cue has been providing all Clubs, as well as the league office, with its integrated Cue platform, which features both the portable Cue Health Monitoring System and easy-to-use Cue COVID-19 tests, throughout the Postseason and World Series. The Cue COVID-19 Test for Home and Over The Counter (OTC) Use is the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without physician supervision or a prescription.

Cue Health Provides Molecular COVID-19 Testing To MLB Clubs During The Postseason And World Series

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (Nasdaq:HLTH), a healthcare technology company, announced today that it will release its third quarter 2021 financial results on Wednesday, November 10, 2021. In conjunction with the release, Cue will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (888) 708-0136 for domestic callers or (929

Cue Health to Announce Third Quarter 2021 Financial Results

NEW YORK and SAN DIEGO, Oct. 14, 2021 /PRNewswire/ -- Cue Health Inc. (Nasdaq: HLTH), a mission-driven healthcare technology company, and the National Basketball Association (NBA) today announced that Cue will serve as the league's Official Home and Point of Care Test for the 2021-22 season. The Cue COVID-19 Test for Home and Over The Counter (OTC) Use is the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without physician supervision or a prescription.

Cue Health To Provide COVID-19 Testing For 2021-22 NBA Season

Alphabet

Cue Health Inc (NASDAQ: HLTH) will collaborate with Google Cloud to add respiratory viral variant sequencing and tracking to its Cue Integrated Care platform.    Cue said it would build Google Cloud's artificial intelligence, machine learning, analytics, and privacy and security tools into its platform, including its Cue Health Monitoring System and rapid molecular COVID-19 test.

Cue Health, Google Cloud Join Forces To Track Respiratory Viral Variants

SAN DIEGO, Oct. 6, 2021 /PRNewswire/ -- Cue Health Inc.  (Nasdaq: HLTH), a mission-driven healthcare technology company, today introduced its new collaboration with Google Cloud to address the nation's critical need for real-time respiratory viral variant sequencing and tracking. The new capabilities will be built into the Cue Integrated Care Platform, which features the Cue Health Monitoring System and first-of-its-kind molecular COVID-19 test -- authorized by the FDA for at-home, over-the-counter use, with accurate results delivered to mobile devices in approximately 20 minutes.

Cue Health Collaborates With Google Cloud To Add Variant Sequencing, Tracking, And Predictive Capabilities To Its Cue Platform

Cue Health Inc., a medical company that has boomed due to its COVID testing products, launched its IPO and raised $200 million last week. Cue Health has released a rapid COVID test under emergency FDA authorization and states that it has tests for other conditions in development.

Cue Health IPO: More Than COVID Testing

Clearwater Analytics Holdings

Clearwater Analytics raised $540 million after selling 30 million shares at $18, above its expected range. Cue Health sold 12.5 million shares at $16, the midpoint of its range.

Clearwater Analytics, Cue Health Set to Trade, Capping a Busy Week for IPOs

CHW Acquisition Corp

DoubleDown Interactive Co Ltd

Focus Universal

OXUS ACQUISITION CORP

Alpine Acquisition Corp

The IPO market saw a quiet end to the summer with only two IPOs this past week. SPAC activity remained steady with seven blank check IPOs. New filers continue to pour into the IPO pipeline, with 11 IPOs, one direct listing, and two SPACs submitting initial filings.

News for Cue Health Stock (HLTH)